Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Colorcon
McKinsey
AstraZeneca
Mallinckrodt

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Rilotumumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Rilotumumab?

Rilotumumab is an investigational drug.

There have been 11 clinical trials for Rilotumumab. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2012.

The most common disease conditions in clinical trials are Stomach Neoplasms, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and Southwest Oncology Group.

There are twelve US patents protecting this investigational drug and two hundred and sixteen international patents.

Recent Clinical Trials for Rilotumumab
TitleSponsorPhase
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric CancerAmgenPhase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNational Cancer Institute (NCI)Phase 2/Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerSouthwest Oncology GroupPhase 2/Phase 3

See all Rilotumumab clinical trials

Clinical Trial Summary for Rilotumumab

Top disease conditions for Rilotumumab
Top clinical trial sponsors for Rilotumumab

See all Rilotumumab clinical trials

US Patents for Rilotumumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Rilotumumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Rilotumumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Rilotumumab   Start Trial Cancer treatment with c-met antagonists and correlation of the latter with HGF expression Genentech, Inc. (South San Francisco, CA)   Start Trial
Rilotumumab   Start Trial Method for predicting efficacy of c-Met inhibitor SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)   Start Trial
Rilotumumab   Start Trial Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)   Start Trial
Rilotumumab   Start Trial P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)   Start Trial
Rilotumumab   Start Trial Meditopes and meditope-binding antibodies and uses thereof City of Hope (Duarte, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Rilotumumab

Drugname Country Document Number Estimated Expiration Related US Patent
Rilotumumab Canada 2900764 2033-02-08   Start Trial
Rilotumumab European Patent Office 2954056 2033-02-08   Start Trial
Rilotumumab Hong Kong 1218930 2033-02-08   Start Trial
Rilotumumab Japan 2016509014 2033-02-08   Start Trial
Rilotumumab World Intellectual Property Organization (WIPO) 2014124326 2033-02-08   Start Trial
Rilotumumab Australia 2013220749 2032-02-15   Start Trial
Rilotumumab Brazil 112014019627 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Boehringer Ingelheim
Colorcon
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.